Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Isabel Cunningham MD

Isabel Cunningham MD

Adjunct Associate Research Scientist, Division of Hematology Oncology, Columbia University College of Physicians and Surgeons, New York, New York

With broad experience in both academic oncology and clinical research, Dr. Cunningham provides a crucial bridge between community and academic medicine. Dr. Cunningham received her AB from Bryn Mawr College and her MD from Yale University School of Medicine. Her postgraduate training included a fellowship in hematology-oncology and bone marrow transplant at Memorial Sloan-Kettering Cancer Center. Dr. Cunningham has held academic positions at Memorial Sloan-Kettering and several other universities, and she is currently conducting research at Columbia University. She has published extensively and has been a reviewer for Blood, Bone Marrow Transplantation, Experimental Hematology, and Leukemia & Lymphoma.

Positions:
Adjunct Associate Research Scientist, Columbia University

Degrees:
Bryn Mawr College, AB
Yale University School of Medicine, MD

Postgraduate Training:
Resident, Internal Medicine, Presbyterian Hospital, New York
Fellow, Hematology/Oncology, Memorial Sloan-Kettering Cancer Center

Board Certifications:
Internal medicine
Hematology

Clinical Interests:
Hematologic malignancies
Extramedullary Leukemia

Disclosures

Dr. Cunningham does not have any financial disclosures.

Recent Contributions to PracticeUpdate:

  1. Asciminib in CML After ABL Kinase Inhibitor Failure
  2. Optimizing CAR T-Cell Therapy for Adults With ALL
  3. 2019 Top Stories in Oncology: Inching Closer to Treatment Discontinuation in CLL
  4. Gilteritinib Superior to Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
  5. Ibrutinib–Rituximab or Chemoimmunotherapy for CLL
  6. Prognostic Impact of Circulating Tumor DNA Status Post Allogeneic HSCT in AML and MDS
  7. ASCO 2019: Updates on CML and CLL Trials
  8. Quizartinib vs Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia
  9. ASCO 2019: Abstract Recommendations From Dr. Isabel Cunningham for Hematologic Malignancies
  10. Real-World Outcomes of Patients Aged ≥75 Years With APL

Most Read This Week

Recently Updated